SOURCE: UV Flu Technologies, Inc.

UV Flu Technologies, Inc.

June 23, 2010 05:00 ET

UV Flu Technologies Ramps Up Sales Program for ViraTech UV-400 Bacterial Air Purifier

CENTERVILLE, MA--(Marketwire - June 23, 2010) -  UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce a 4-fold upsurge in its sales force with a dramatic increase currently totaling 120 representatives and growing. This announcement is followed by news that the Company has begun offering the latest generation UV-400 into the residential marketplace for the very first time.

Sales efforts are now easily capable of fully developing and taking advantage of growing distribution channels aimed at penetrating mainstream markets based on percentages that track the Company's efforts. Early indicators show the Medical sector leading the charge at 55%, followed by Sports/Leisure with 15%, Commercial/Industrial at 10% and Hotels/Senior Living and the Residential sector both also at a 10% share.

The medical sector represents the Company's initial focus for early adoption as this area brings into focus singular and important credence to the products laboratory test veracity and bolsters its brand position as one of the very few FDA certified medical devices in the air quality field. Recent news of the highly favorable evaluation results at New England Baptist Hospital and Massachusetts General Hospital have proven to be instrumental in driving awareness across the country.

"Now that shipments of our recently improved, state-of-the-art UV-400 air purifier are about to arrive at our shipment depot in Boston, we have seen consumer interest spike, and the increased commitment and growth within our distribution network result in the fielding of a large and capable sales team ready to get out and spread the word about this important health care product. We are well on the way to our near term goal of 200 active sales reps by the end of July," said Jack Lennon, President of UV Flu Technologies.

"The excitement for our product has been increasing exponentially, and in response, we moved up our timetable for introducing residential market sales accordingly. When it comes to the health and safety of family members, those responsible clearly want to invest in the very best solutions and our combination of high quality, long life design, plus ease of use and verifiable lab results makes it a simple decision for most everyone," said Mr. Lennon.

The Company plans to announce delivery and commercial availability of the newly updated product shortly. Those interested in the product, or wishing to pre-order are invited to contact the distributor, Puravair LLC at 1-866-6-PURAVAIR or by email at

Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.


UV Flu Technologies, Inc.
John J. Lennon, President & CEO

Contact Information

  • Investor Information:
    Geaux IR Services, Inc.
    Toll-Free: 1-888-355-8838
    Email Contact